ESR1 and breast carcinoma: Altogether, the results indicate that UBE2M silencing increases the sensitivity of ER+ breast cancer cells to fulvestrant by inducing cell cycle arrest and apoptosis, suggesting that UBE2M is a potential driver of fulvestrant resistance.